Editas Medicine (EDIT) Reports Q3 Loss of $0.66
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines
November 12, 2019 7:13 AM ESTEditas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (NASDAQ: CELG) under which the parties may research, develop, and commercialize autologous and... More
